Joseph Gagnon
Psychiatric/Mental Health · Chesterbrook, PANPI 1558904813
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,558 of the $63,901 with a category attached, or 68.2%. 24 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 45.4% of the total. Reporting peaked in 2022 at $19,254 and has fallen 67.4% since, to $6,281 in 2025. Among psychiatric/mental health clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 389 payments — averaging $164.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$29K
- Neos Therapeutics, LP$17K
- AbbVie$6K
- E.r. Squibb & Sons, L.L.C.$4K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$4K
- Corium, LLC$2K
- plus $2K from 18 others
What the payments were for
- Consulting fees$14,06122%
- Speaking & faculty fees$43,55868%
- Travel & lodging$8761%
- Food & beverage$5,3548%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 39 | $29,017 |
| Neos Therapeutics, LP | 149 | $16,743 |
| AbbVie | 67 | $6,084 |
| E.r. Squibb & Sons, L.L.C. | 7 | $4,293 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $3,703 |
| Corium, LLC | 48 | $1,941 |
| Teva Pharmaceuticals USA, Inc. | 5 | $1,105 |
| Sunovion Pharmaceuticals Inc. | 10 | $193 |
| Bausch Health US, LLC | 9 | $126 |
| Johnson & Johnson | 6 | $106 |
| Collegium Pharmaceutical, Inc. | 5 | $103 |
| Ironshore Pharmaceuticals Inc. | 4 | $91 |
| Axsome Therapeutics, Inc. | 3 | $67 |
| Vanda Pharmaceuticals Inc. | 3 | $63 |
| Lundbeck LLC | 3 | $45 |
| Noven Therapeutics, LLC | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Tris Pharma Inc | 2 | $34 |
| Indivior Inc. | 1 | $23 |
| Novo Nordisk | 1 | $21 |
| Adlon Therapeutics L.p. | 1 | $19 |
| Alkermes, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$28,487
- Adzenys XR-ODT$14,900
- Cotempla XR-ODT$11,700
- VRAYLAR$5,175
- CAPLYTA$3,379
- COBENFY$1,540
- Azstarys$1,223
- Austedo XR$1,000
How this compares
$63,901 in reported general payments places this provider in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $91,199 |
| ClozarilClozapine | 18 | $36,744 |
| Abilify MaintenaAripiprazole | 12 | $36,196 |
| VraylarCariprazine Hcl | 13 | $15,654 |
| Paliperidone ErPaliperidone | 50 | $7,984 |
| Fluphenazine Hcl | 40 | $5,907 |
| Dyanavel XrAmphetamine | 12 | $5,391 |
| Lisdexamfetamine Dimesylate | 23 | $5,018 |
| Clomipramine Hcl | 12 | $4,498 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 124 | $4,004 |
| Clozapine | 46 | $3,461 |
| Haloperidol | 39 | $1,057 |
| Quetiapine Fumarate | 102 | $970 |
| Benztropine Mesylate | 85 | $808 |
| Risperidone | 56 | $715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $29,017 | $91,19911 claims |
| AbbVieVraylar | $6,084 | $15,65413 claims |
| Tris Pharma IncDyanavel Xr | $34 | $5,39112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Chesterbrook
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
- Dylan KilmerGreenfield Township$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.